文献速递妇科

BRCA1/2突变者降低风险输卵管卵巢切除术的 uptake 与时机

Uptake and timing of risk-reducing salpingo-oophorectomy among patients with BRCA1 and BRCA2 mutations.
PubMed 文献 · Am J Obstet Gynecol · 2021-06-23

该回顾性图表综述纳入2012-2021年638例BRCA1/2突变携带者,评估降低风险输卵管卵巢切除术的 uptake 和时机是否符合NCCN指南。48.0%已行该手术,21.3%时机及时,37.5%延迟,延迟最常见原因是BRCA突变识别延迟(78.7%)。

要点

  • 638例BRCA1/2突变者中48.0%已行降低风险输卵管卵巢切除术,37.5%延迟。
  • 延迟者BRCA突变识别延迟占78.7%,为最常见原因。
  • BRCA2突变者及时手术几率是BRCA1突变者的7.54倍。

核心结论

  • 近38%的BRCA1/2突变携带者在NCCN推荐年龄之后才接受或尚未接受降低风险输卵管卵巢切除术。
  • 延迟最常见原因是BRCA突变识别延迟,占延迟者的78.7%。
  • 及时基因检测可提高BRCA突变者适时行降低风险输卵管卵巢切除术的比例。

研究设计与样本

  • 回顾性图表综述,纳入2012-2021年间与提供者讨论过降低风险输卵管卵巢切除术的BRCA1/2突变女性638例。
  • 根据NCCN指南将患者分类为及时或延迟行降低风险输卵管卵巢切除术,并收集延迟原因。
  • 采用比较统计分析和多变量逻辑回归模型评估与手术时机相关的因素。

主要发现

  • 638例中306例(48.0%)已行降低风险输卵管卵巢切除术,332例(52.0%)未行。
  • 136例(21.3%)及时手术,239例(37.5%)延迟,263例(41.2%)未手术但年龄小于NCCN指南推荐。
  • 延迟组基因检测时年龄显著大于及时组(平均49.8岁 vs 36.3岁;P<.001)。
  • 已手术者中,延迟组从BRCA确诊到手术的间隔显著短于及时组(中位8.7个月 vs 17.6个月;P<.001)。
  • 延迟组有个人癌症史的比例高于及时组(49.8% vs 37.5%;P=.028)。

关键数值与推荐

  • NCCN推荐BRCA1突变携带者在35-40岁、BRCA2突变携带者在40-45岁或完成生育后行降低风险双侧输卵管卵巢切除术。
  • 延迟原因:188例(78.7%)BRCA突变识别延迟,29例(12.1%)更年期担忧,17例(7.1%)正在接受癌症治疗,12例(5.0%)需与乳腺手术协调,20例(8.4%)其他原因,19例(7.9%)未记录原因。
  • 多变量模型中,BRCA诊断年龄较大与延迟手术时机显著相关(OR 0.73;95%CI 0.68-0.78;P<.001)。
  • BRCA2突变者及时手术的几率是BRCA1突变者的7.54倍(OR 7.54;95%CI 3.70-16.42;P<.001)。

临床怎么用

  • 对符合条件者及时进行BRCA基因检测,以增加适时行降低风险输卵管卵巢切除术的机会。
  • 关注BRCA突变识别延迟这一主要可干预因素,优化转诊和检测流程。
  • 对有更年期担忧或个人癌症史的患者,个体化咨询手术时机与支持措施。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In women with BRCA mutations, risk-reducing bilateral salpingo-oophorectomy has been shown to decrease gynecologic cancer-specific and overall mortality. The National Comprehensive Cancer Network recommends that patients with BRCA mutations undergo risk-reducing bilateral salpingo-oophorectomy between the ages of 35 and 40 years for BRCA1 mutation carriers and between the ages of 40 and 45 years for BRCA2 mutation carriers or after childbearing is complete. Currently, uptake and timing of risk-reducing bilateral salpingo-oophorectomy and reasons for delays in risk-reducing bilateral salpingo-oophorectomy are not well understood. OBJECTIVE: We sought to evaluate uptake and timing of risk-reducing bilateral salpingo-oophorectomy among women with BRCA1 and BRCA2 mutations concerning the National Comprehensive Cancer Network guidelines and reasons for delays in risk-reducing bilateral salpingo-oophorectomy. STUDY DESIGN: In this retrospective chart review, we identified women with BRCA1 and BRCA2 mutations who discussed risk-reducing bilateral salpingo-oophorectomy with a provider between 2012 and 2021. Uptake of risk-reducing bilateral salpingo-oophorectomy was documented, and patients were classified as having timely or delay in risk-reducing bilateral salpingo-oophorectomy based on the National Comprehensive Cancer Network guidelines. For those with delay in risk-reducing bilateral salpingo-oophorectomy, reasons cited for delay were collected. Comparative statistical analyses were performed to evaluate characteristics of those with timely vs delayed risk-reducing bilateral salpingo-oophorectomy. A multivariable logistic regression model was used to evaluate the associations among factors related to timing of risk-reducing bilateral salpingo-oophorectomy. RESULTS: We identified 638 BRCA1 and BRCA2 mutation carriers seen between 2012 and 2021. Of these patients, 306 (48.0%) had undergone risk-reducing bilateral salpingo-oophorectomy and 332 (52.0%) had not. When evaluating the timing of risk-reducing bilateral salpingo-oophorectomy, 136 (21.3%) underwent timely risk-reducing bilateral salpingo-oophorectomy, 239 (37.5%) had delays in risk-reducing bilateral salpingo-oophorectomy, and 263 (41.2%) had not undergone risk-reducing bilateral salpingo-oophorectomy but were younger than the National Comprehensive Cancer Network age guidelines; therefore, they were neither timely nor delayed. Patients with delay in risk-reducing bilateral salpingo-oophorectomy were significantly older at the time of genetic testing than those with timely risk-reducing bilateral salpingo-oophorectomy (mean, 49.8 vs 36.3 years; P<.001). Of the 306 patients who underwent risk-reducing bilateral salpingo-oophorectomy, those with delayed risk-reducing bilateral salpingo-oophorectomy had a significantly shorter interval between BRCA identification and risk-reducing bilateral salpingo-oophorectomy than those with timely risk-reducing bilateral salpingo-oophorectomy (median, 8.7 vs 17.6 months; P<.001). Patients with delay in risk-reducing bilateral salpingo-oophorectomy were more likely to have a personal history of cancer than those with timely risk-reducing bilateral salpingo-oophorectomy (49.8% vs 37.5%; P=.028). Of the 239 women with delay in risk-reducing bilateral salpingo-oophorectomy, 188 (78.7%) had delayed BRCA mutation identification, 29 (12.1%) had menopausal concerns, 17 (7.1%) had ongoing cancer treatment, 12 (5.0%) had coordination with breast surgery, 20 (8.4%) had miscellaneous reasons, and 19 (7.9%) had no reason documented. In the multivariate model, older age at BRCA diagnosis (odds ratio, 0.73; 95% confidence interval, 0.68-0.78; P<.001) was significantly associated with delayed risk-reducing bilateral salpingo-oophorectomy timing; those with BRCA2 mutation type were 7.54 times as likely to have timely risk-reducing bilateral salpingo-oophorectomy than BRCA1 mutation carriers (odds ratio, 7.54; 95% confidence, 3.70-16.42; P<.001). CONCLUSION: Nearly 38% of BRCA1 and BRCA2 mutation carriers undergo or have yet to undergo risk-reducing bilateral salpingo-oophorectomy over the recommended National Comprehensive Cancer Network age. The most common reason for the delay in risk-reducing bilateral salpingo-oophorectomy was delayed identification of BRCA mutation, noted in 79% of patients with delayed risk-reducing bilateral salpingo-oophorectomy. Timely genetic testing for eligible patients can increase appropriately timed risk-reducing bilateral salpingo-oophorectomy for the prevention of ovarian cancer and reduction of mortality in BRCA mutation carriers.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Smith MJ, Gerber D, Olsen A, et al. Uptake and timing of risk-reducing salpingo-oophorectomy among patients with BRCA1 and BRCA2 mutations. Am J Obstet Gynecol. 2021. PMID: 34171390. doi:10.1016/j.ajog.2021.06.070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。